Evidence and Access Archives

Publication

Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation in the United States

Authors: Joseph McGuirk, Clint Divine, Seung Hyun Moon, Aastha Chandak, Zhiji Zhang, Genovefa A. Papanicolaou…

CertaraApril 8, 2021

Press Coverage

Legislators: Bring all stakeholders to the table to lower drug costs

BY ROMAN CASCIANO, OPINION CONTRIBUTOR — 03/29/21 05:30 PM EDT No one is happy with the…

CertaraMarch 30, 2021

On-Demand Webinar

Strategic Evidence & Value Communication Symposium

Join us on Wednesday, April 21, 2021, from12:00 PM – 2:00 PM EDT for Certara’s…

CertaraMarch 26, 2021

Blog

Getting Gene Therapies to Patients

This blog discusses the challenges that drug developers face in getting patients access to cell…

CertaraFebruary 16, 2021

Case Study

Early Value Assessment in Gene Therapy Clinical Trial Design

A global biotechnology company engineering precision genetic medicine for rare diseases was in need of…

CertaraFebruary 12, 2021

Press Coverage

Getting Real with RWE

By Taren Grom Real-world evidence, important for regulatory decision-making, is beginning to touch all areas…

CertaraNovember 20, 2020

On-Demand Webinar

SNDS: Strengths, Limitations and Perspectives for the Largest and Richest Real-World Database in EU

In this webinar, our experts provided an overview of the SNDS and the key working…

CertaraOctober 20, 2020

Case Study

Reimbursement and Launch Planning

CertaraJune 22, 2020

On-Demand Webinar

The Rare Disease Drug Dilemma: Great Value, High Price, Limited Access?

This webinar will explain how pricing has evolved for the rare disease drug market and…

CertaraFebruary 19, 2020

On-Demand Webinar

Innovative Solutions for Fast-Tracking Drugs for Rare Diseases

This webinar discussed which pharmaceutical payer strategies work and which don't in our rapidly changing…

CertaraAugust 10, 2019

Evidence and Access

Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation in the United States

Legislators: Bring all stakeholders to the table to lower drug costs

Strategic Evidence & Value Communication Symposium

Getting Gene Therapies to Patients

Early Value Assessment in Gene Therapy Clinical Trial Design

Getting Real with RWE

SNDS: Strengths, Limitations and Perspectives for the Largest and Richest Real-World Database in EU

Reimbursement and Launch Planning

The Rare Disease Drug Dilemma: Great Value, High Price, Limited Access?

Innovative Solutions for Fast-Tracking Drugs for Rare Diseases

Newsletter sign up

Quick links

Solutions

Contact